• NervAlign® Nerve Cuff approved for use in DoD and VA healthcare systems
• Initial order and reorder received from the DoD and VA network
• Further validation of the quality of NervAlign® in peripheral nerve repair

ReNerve Limited (ASX, 'ReNerve' or 'the Company'), a leading Australian medical device innovator focused on solutions for peripheral nerve injury (PNI), is pleased to announce that its NervAlign® Nerve Cuff has been approved for use across the US Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems, representing a significant endorsement of ReNerve's NervAlign® nerve cuff technology. The approval allows the NervAlign® Nerve Cuff to be used across the DoD's 51 military hospitals and 424 clinics, as well as VA's 170 medical centres and over 1,193 outpatient facilities, providing ready access to this innovative technology to those of the approximately 9.5 million patients across both healthcare systems who may benefit from its use. Under this approval, ReNerve has received both an initial purchase order and a subsequent repeat order from federal medical facilities, demonstrating early confidence in the NervAlign® system. These orders will enable immediate deployment of the technology to select facilities within both the DoD and VA networks, with a broader rollout planned for the coming months. 'This approval represents major progress in our mission to provide superior nerve repair solutions to those who need them most,' said Dr Julian Chick, CEO of ReNerve. 'Military service members and veterans often face complex peripheral nerve injuries, and we are honoured and proud that the NervAlign® Nerve Cuff will now be available to support their recovery and rehabilitation.' The NervAlign® Nerve Cuff represents a significant advancement in peripheral nerve repair technology, offering clinicians a precise and effective solution for supporting nerve regeneration and recovery following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. The company's high-margin, scalable products are positioning it as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.

ReNerve is advancing a complete suite of nerve repair solutions, including the NervAlign® Nerve Cuff, Deep Dermal tissue product, Amniotic tissue product ranges, NervAlign® Nerve Conduit Range, and NervAlign® Nerve Guide Matrix. The company's cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.